Shares of Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR - Get Free Report) saw strong trading volume on Monday . 5,739 shares were traded during trading, a decline of 5% from the previous session's volume of 6,045 shares.The stock last traded at $10.97 and had previously closed at $10.82.
Analyst Ratings Changes
Several equities research analysts have commented on PHAR shares. HC Wainwright restated a "buy" rating and issued a $37.00 target price on shares of Pharming Group in a research note on Thursday, March 20th. Oppenheimer increased their target price on shares of Pharming Group from $30.00 to $39.00 and gave the stock an "outperform" rating in a report on Friday, March 14th.
Get Our Latest Stock Analysis on Pharming Group
Pharming Group Stock Performance
The stock has a market capitalization of $714.25 million, a P/E ratio of -52.49 and a beta of 0.02. The company has a quick ratio of 2.00, a current ratio of 2.76 and a debt-to-equity ratio of 0.39. The stock has a 50 day simple moving average of $10.26 and a two-hundred day simple moving average of $9.38.
Pharming Group (NASDAQ:PHAR - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.25) by $0.03. Pharming Group had a negative net margin of 4.14% and a negative return on equity of 6.01%. The firm had revenue of $79.09 million for the quarter, compared to analyst estimates of $67.74 million. On average, equities analysts forecast that Pharming Group N.V. Sponsored ADR will post -0.2 EPS for the current fiscal year.
Pharming Group Company Profile
(
Get Free Report)
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.
Further Reading
Before you consider Pharming Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharming Group wasn't on the list.
While Pharming Group currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
